Strategic Signals Weekly: April 26 – May 03, 2026
May 3, 2026
Genprex, Inc. strategic review ongoing (Reqorsa® Gene Therapy (quaratusugene ozeplasmid)). 20 signals this week: 3 licensing, 3 strategic, 13 financing.
Data for the Business of Biotech
Primary-source biotech data, structured for analysts, BD teams, and the AI tools they're building.
Analysis-ready biotech datasets
Structured data from primary sources, documented for analysts and AI workflows. Custom scopes available on request.
FDA Drug Exclusivity Data
Orange Book exclusivity records with patent coverage, approved indications, ANDA/NDA filings, and normalized company identifiers. Full monthly change history from October 2023.
More information →
Clinical Trial Change Feed
Structured delta of daily changes across 450K+ ClinicalTrials.gov records: status changes, protocol amendments, endpoint modifications, enrollment shifts, and new site additions. Filterable by condition, sponsor, or geography.
More information →
Biotech BD & Licensing Events
Auto-classified 8-K events from SEC filings: licensing agreements, strategic alternatives, M&A signals, and financing activity. Tagged by deal type, linked to company identifiers.
More information →
Biotech Hedge Fund Positions
13D/13G ownership filings and 13F institutional holdings for biotech-focused funds. New positions, stake reductions, and activist threshold crossings, linked to company and trial identifiers.
More information →
Built on primary sources, harmonized across datasets
RxDataLab pulls from ClinicalTrials.gov, SEC EDGAR, USPTO patent records, and FDA data feeds then harmonizes company names, enriches with metadata, links identifiers, and tracks changes over time. Every data point traces back to the original filing. We also publish original analysis from the same pipelines.
Also available on the platform
Data platform live at app.rxdatalab.com
All RxDataLab datasets in one place, updated daily. Company pages, clinical program views, and linked research tools. A subscription for teams who want a dashboard.
Clinical Trial Tracker
Pipeline changes, trial status updates, and competitive landscape mapping across 450K+ trials.
BioHedge
Hedge fund positioning in biotech stocks, updated from Schedule 13 filings.
Strategic Signals
Deal activity, partnership filings, and BD events directly from SEC 8-K filings.
Insider Activity
Executive and director trades filed with the SEC, linked to company pipelines.
Research & Resources
Recent Analysis
View all →BioHedge Weekly: April 26 – May 03, 2026
May 3, 2026
RA Capital Management initiated new 9.9% position in Prelude Therapeutics Inc. 6 filings this week, 3 activist, 3 passive.
Specialist Fund Concentration in DMD Treatments: Pipeline and Mechanisms
April 9, 2026
Duchenne muscular dystrophy has attracted an unusual concentration of specialist biotech hedge fund interest. We mapped interventional trials across 10 companies and overlaid beneficial ownership data from 18 specialist funds to show where that consensus sits and why.
Traceable data for BD, investors, and strategy teams
We deliver harmonized, primary-source datasets for BD teams, investors, and the AI tools they’re building. Every data point traces back to the original filing. Tell us what you’re tracking.
or email [email protected]